目的:评价局部晚期不可手术的非小细胞肺癌同步放化疗的疗效和安全性.方法:对62例经细胞学或病理学明确诊断的局部晚期非小细胞肺癌患者进行同步放化疗,4个周期的NP加上同步放疗,第1周期NP化疗第1天就开始实施放疗.放疗采用15MV -X线,3D - CRT常规分割照射,总剂量60Gy.结果:可评价的60例患者,完全缓解11例,部分缓解36例,稳定11例,进展2例,总有效率为78.3％,1年、2年、3年生存率分别为90％,48.3％和23.3％,中位生存时间为23.2个月.结论:疗前正确评估合适的局部晚期非小细胞肺癌患者,同步放化疗有较好的1年、2年、3年生存率及中位生存时间,毒副反应多能耐受.%Objective:To evaluate the efficacy and safety of concurrent chemoradiotherapy in patients with locally advanced non - small cell lung cancer. Methods: All 62 patients diagnosised as locally advanced non - small cell lung cancer by clear cytology or pathology accepted 3D - CRT of thoracic radiotherapy and concurrent chemotherapy of NP. 3D - CRT, started on day I in the first cycle of NP chemotherapy. Chemotherapy was carried out for 4 cycles, every cycle 21 days. Thoracic radiotherapy adopted 3D - CRT of 15MV - X ray with conventional fractionated irradiation, a total dose of 60 Gy. Results; In 60 evaluable patients, there were 11 cases complete response 36 cases had partial response (PR) , llcases with no change(NC) and 2 cases with progression disease (PD). The overall response rates were 78.3% .1,2,3 year survival rate was 90% ,48.3% and 23.3% , respectively, and a median survival time was 23.2 months. Conclusion: For patients with locally advanced unresectable non -small cell lung cancer concurrent chemoradiotherapy is effective and have a good 1,2,3- year survival rate, median survival time, and side effects are tolerable.
展开▼
